When should diltiazem be held in a 72‑year‑old bed‑bound female nursing‑home resident?

When to Hold Diltiazem in a 72-Year-Old Bedbound Nursing Home Resident

Hold diltiazem immediately if systolic blood pressure falls below 90 mmHg, heart rate drops below 50 bpm, or if the patient develops symptomatic bradycardia, dizziness, or signs of decompensated heart failure. 1

Absolute Contraindications Requiring Immediate Discontinuation

Hold diltiazem permanently in the presence of: 1

• Second- or third-degree AV block (unless a functioning pacemaker is present)
• Sick sinus syndrome without a pacemaker
• Decompensated systolic heart failure or severe left ventricular dysfunction
• Cardiogenic shock
• Hypotension (systolic BP <90 mmHg or symptomatic)
• Wolff-Parkinson-White syndrome with atrial fibrillation or atrial flutter

Critical Monitoring Parameters in This High-Risk Population

For a bedbound nursing home resident, check the following before each dose: 1

• Blood pressure: Hold if systolic <90 mmHg or if patient reports dizziness/lightheadedness
• Heart rate: Hold if <50 bpm or if symptomatic bradycardia develops
• Signs of heart failure: Hold if new or worsening dyspnea, peripheral edema, or orthopnea develops

Special Considerations for Frail Elderly Nursing Home Residents

This patient population requires heightened vigilance because: 1

• Diltiazem is associated with increased fall risk in elderly patients, with an odds ratio of 1.8 for multiple falls 2
• Polypharmacy is common in nursing homes (affecting 29-45% of residents), increasing risk of drug-drug interactions 1
• Bedbound status indicates frailty and functional impairment, making adverse effects more consequential 1

Drug Interactions Requiring Dose Holding or Adjustment

Hold diltiazem temporarily if the patient is newly started on: 1, 3

• Other AV nodal blocking agents (beta-blockers, digoxin, amiodarone) - risk of severe bradycardia or heart block
• Medications causing hypotension - additive effects may precipitate falls
• CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir) - significantly increase diltiazem levels

Consider permanent discontinuation if: 3, 4

• Patient is on direct oral anticoagulants (DOACs) - diltiazem increases major bleeding risk (OR 1.38) and GI bleeding risk (OR 1.19) 4
• Patient develops drug-induced somnolence with CYP3A4-metabolized medications 5

Hepatic and Renal Dysfunction

Hold and reassess dosing if: 1, 3

• Hepatic dysfunction develops (monitor liver function tests) - diltiazem can cause abnormal liver function and rare acute hepatic injury
• Renal dysfunction worsens - requires dose adjustment and increased monitoring

Practical Algorithm for Daily Assessment

Before administering each dose, nursing staff should: 1

1. Measure vital signs: Hold if HR <50 or SBP <90 mmHg
2. Assess symptoms: Hold if patient reports dizziness, weakness, or difficulty breathing
3. Check for new medications: Hold if new AV nodal blockers or CYP3A4 inhibitors added
4. Evaluate functional status: Hold if new falls, increased confusion, or worsening mobility

Common Pitfalls to Avoid

• Do not assume stable dosing is safe - elderly patients' hemodynamics can change rapidly with dehydration, infection, or medication changes 1
• Do not overlook drug interactions - 80.8% of patients on ≥10 medications experience drug-drug interactions 1
• Do not continue diltiazem "because it's always been prescribed" - deprescribing should be considered when harm outweighs benefit in frail elderly 1
• Monitor standing blood pressure if patient has any mobility, as orthostatic hypotension increases fall risk 2

When to Consider Permanent Discontinuation

Strongly consider deprescribing diltiazem if: 1

• Patient has limited life expectancy (<6 months) and symptom control is the priority
• Recurrent hypotension or bradycardia despite dose reduction
• Falls or near-falls temporally related to dosing
• No clear ongoing indication (e.g., atrial fibrillation now rate-controlled, hypertension resolved)
• Polypharmacy burden is high (≥9 medications) and adverse drug events are occurring 1